Dermata Therapeutics Stock News

Dermata Therapeutics (NASDAQ:DRMA) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, Dermata Therapeutics Inc. is a privately held biotechnology company. It focused on treatment of medical and aesthetic skin diseases and conditions. The companys product pipeline consist []

Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic skin conditions. DMT410 showed im

Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearanceDuration of effect lasted approximately 3 monthsNo potential distant spread of toxin observedSAN DIEGO, C

(PR-inside.com) Topline results expected in second half of 2022 Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focused on the development of novel dermatology therapies for the medial and aesthetic markets, today announced it has enrolled the first patient in its Phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea. DMT310 is Dermata''s lead product candidate, consisting of a once-weekly topical treatment with both mechanical and chemical mechanisms of action, currently being investigated to treat ..

- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis -- Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market -- Topline results from DMT410 POC study in multiple …

SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and

- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 -

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | P

Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of almost 164%.